Abbott Laboratories $ABT Position Boosted by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC raised its position in Abbott Laboratories (NYSE:ABT) by 1.6% during the second quarter, HoldingsChannel.com reports. The firm owned 179,578 shares of the healthcare product maker’s stock after buying an additional 2,852 shares during the quarter. Abbott Laboratories comprises 1.4% of Cyndeo Wealth Partners LLC’s investment portfolio, making the stock its 7th biggest position. Cyndeo Wealth Partners LLC’s holdings in Abbott Laboratories were worth $24,424,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ABT. Brighton Jones LLC raised its holdings in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares during the period. Wealthcare Advisory Partners LLC raised its holdings in shares of Abbott Laboratories by 8.4% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 13,282 shares of the healthcare product maker’s stock valued at $1,762,000 after buying an additional 1,024 shares during the period. GAMMA Investing LLC raised its holdings in shares of Abbott Laboratories by 17.0% during the 1st quarter. GAMMA Investing LLC now owns 38,467 shares of the healthcare product maker’s stock valued at $5,103,000 after buying an additional 5,590 shares during the period. Integrated Advisors Network LLC raised its holdings in shares of Abbott Laboratories by 30.9% during the 1st quarter. Integrated Advisors Network LLC now owns 26,003 shares of the healthcare product maker’s stock valued at $3,449,000 after buying an additional 6,131 shares during the period. Finally, Redhawk Wealth Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $297,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ABT. Wells Fargo & Company dropped their target price on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a report on Friday, July 18th. Raymond James Financial dropped their target price on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating on the stock in a report on Friday, July 18th. Royal Bank Of Canada raised their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Evercore ISI lifted their price objective on Abbott Laboratories from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, BTIG Research dropped their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $146.24.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $133.24 on Friday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $231.90 billion, a price-to-earnings ratio of 16.70, a price-to-earnings-growth ratio of 2.55 and a beta of 0.69. The business has a 50 day simple moving average of $132.44 and a 200-day simple moving average of $131.52.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the previous year, the business earned $1.14 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.